Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus PANWARFIN.
EDOXABAN vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
60 mg orally once daily
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category C
Category C
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."